Table 2.
Progression-free and overall survival in patients with CTCs
| (A) Progression-free survival | ||||||
|---|---|---|---|---|---|---|
| Variable name | Status | Number | Relapses (%) | Relapse free survival proportion at 48 months (%) | 95 % C.I. | P Values by log-rank test |
| By number of circulating tumor cells | ||||||
| One or more circulating tumor cells | + | 23 | 9/23 (39 %) | 61 | 38–77 | 0.002 |
| − | 71 | 10/71 (14 %) | 84 | 72–92 | ||
| Two or more circulating tumor cells | + | 6 | 4/6 (67 %) | 33 | 5–68 | ≤0.0001 |
| − | 88 | 15/88 (17 %) | 81 | 70–86 | ||
| Three or more circulating tumor cells | + | 5 | 4/5 (80 %) | 20 | 1–58 | ≤0.0001 |
| − | 89 | 15/89 (17 %) | 81 | 70–89 | ||
| (B) Overall survival | ||||||
|---|---|---|---|---|---|---|
| Variable name | Status | Number | Deaths (%) | Overall survival proportion at 48 months (%) | 95 % C.I. | P Values by log-rank test |
| By number of circulating tumor cells | ||||||
| One or more circulating tumor cells | + | 23 | 6/23 (26 %) | 70 | 45–86 | 0.09 |
| − | 71 | 9/71 (13 %) | 86 | 74–93 | ||
| Two or more circulating tumor cells | + | 6 | 3/6 (50 %) | 30 | 1–72 | 0.0004 |
| − | 88 | 12/88 (14 %) | 85 | 74–91 | ||
| Three or more circulating tumor cells | + | 5 | 3/5 (60 %) | 30 | 1–72 | 0.0004 |
| − | 89 | 12/89 (13 %) | 85 | 74–91 | ||